Miguel Valdovinos

Dr. Miguel Valdovinos


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
PDF file
JRJosé María Remes-Troche
José María Remes-Troche
ECEnrique Coss-Adame
Enrique Coss-Adame
MVMiguel Valdovinos
Miguel Valdovinos
OGOctavio Gómez-Escudero
Octavio Gómez-Escudero
MIMaría Eugenia Icaza-Chávez
María Eugenia Icaza-Chávez
RORodolfo Solana Ortiz
Rodolfo Solana Ortiz
Dysbiosis, a loss of balance between resident bacterial communities and their host, is associated with multiple diseases, including inflammatory bowel diseases (nonspecific chronic ulcerative colitis and Crohn’s disease), and digestive functional disorders. Probiotics, prebiotics, synbiotic organisms and, more recently, pharmabiotics, have been shown to modulate the human microbiota. In this review, we provide an overview of the key concepts relating to probiotics, prebiotics, synbiotic organisms, and pharmabiotics, with a focus on available clinical evidence regarding the specific use of a unique pharmabiotic, the strain Lactobacillus acidophilus LB (Lactobacillus boucardii), for the management of gastrointestinal disorders. Since it does not contain living organisms, the administration of L. acidophilus LB is effective and safe as an adjuvant in the treatment of acute diarrhea, chronic diarrhea, and antibiotic-associated diarrhea, even in the presence of immunosuppression.

7 November 2014 in Current Gastroenterology Reports
Verified
Journal Article
Closed access
PDF file
MVMiguel Valdovinos
Miguel Valdovinos
MZMonica R. Zavala-Solares
Monica R. Zavala-Solares
ECEnrique Coss-Adame
Enrique Coss-Adame

2 December 2022 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
JFJanette Furuzawa-Carballeda
Janette Furuzawa-Carballeda
MIMaría E. Icaza‐Chávez
María E. Icaza‐Chávez
DADiana Aguilar‐León
Diana Aguilar‐León
NUNorma Uribe‐Uribe
Norma Uribe‐Uribe
MNMaría C. Nuñez‐Pompa
María C. Nuñez‐Pompa
GTGonzalo Torres-Villalobos
Gonzalo Torres-Villalobos

10 August 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
Brenda Hildeliza Camacho DíazBrenda Hildeliza Camacho Díaz
Brenda Hildeliza Camacho Díaz
MOMartha Lucía Arenas Ocampo
Martha Lucía Arenas Ocampo
POPerla Osorio-Diaz
Perla Osorio-Diaz
AJAntonio Ruperto Jiménez-Aparicio
Antonio Ruperto Jiménez-Aparicio
GJGuadalupe Monserrat Alvarado Jasso
Guadalupe Monserrat Alvarado Jasso
EGElisa Gómez-Reyes
Elisa Gómez-Reyes
Irritable bowel syndrome displays three different subtypes: constipation (IBS-C), diarrhea (IBS-D), and mixed (IBS-M). Treatment with dietary fiber is used, with consideration given both to the chemical composition of the fiber and to the different subtypes of IBS. The IBS-D subtype is usually treated with a low-FODMAPs diet, whereas the IBS-C subtype suggests prebiotics and probiotics to promote microbiota restoration. The aim of this study was to assess the effects of employing agave fructans as the soluble fiber of a jelly (Gelyfun®gastro) containing 8 g per serving in the IBS-C group (n = 50), using a randomized, double-blind, time-limited trial for four weeks. We evaluated changes in the frequency and types of bowel movements through the Bristol scale, and the improvement of the condition was evaluated using quality of life (IBS-QOL) and anxiety–depression (HADS) scales. The main results were that the number of bowel movements increased by more than 80%, with at least one stool per day from fifteen days onwards, without a laxative effect for the group treated. Finally, the quality of life with the prebiotic jelly was significantly improved compared to the placebo in all specific domains, in addition to significantly reducing anxiety and depression.

1 April 2017 in Revista de Gastroenterología de México
Verified
Journal Article
Open access
MVMiguel Valdovinos
Miguel Valdovinos
EME. Montijo
E. Montijo
AAA.T. Abreu
A.T. Abreu
SHS. Heller
S. Heller
AGA. González-Garay
A. González-Garay
FGFrancisco Guarner
Francisco Guarner
Probiotics are frequently prescribed in clinical practice. Their efficacy in treating gastrointestinal disorders is supported by a significant number of clinical trials. However, the correct prescription of these agents is hampered due to a lack of knowledge of the scientific evidence and to the different presentations and microbial compositions of the probiotics that are currently available. To provide the clinician with a consensus review of probiotics and recommendations for their use in gastroenterology. Controlled clinical trials, meta-analyses, and systematic reviews published up to 2015 were selected, using the MESH terms: probiotics, gastrointestinal diseases, humans, adults, AND children. The Delphi method was employed. Eighteen gastroenterologists treating adult patients and 14 pediatric gastroenterologists formulated statements that were voted on until agreement>70% was reached. The level of evidence based on the GRADE system was evaluated for each statement. Eleven statements on the general concepts of probiotics and 27 statements on the use of probiotics in gastrointestinal diseases in both adults and children were formulated. The consensus group recommends the use of probiotics under the following clinical conditions: the prevention of diarrhea associated with antibiotics, the treatment of acute infectious diarrhea, the prevention of Clostridium difficile infection and necrotizing enterocolitis, the reduction of adverse events from Helicobacter pylori eradication therapy, relief from irritable bowel syndrome symptoms, the treatment of functional constipation in the adult, and the induction and maintenance of remission in patients with ulcerative colitis and pouchitis, and the treatment of covert and overt hepatic encephalopathy.

7 March 2022 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
APAngel Alexis Priego-Ranero
Angel Alexis Priego-Ranero
Ghislain OpdenakkerGhislain Opdenakker
Ghislain Opdenakker
NUNorma Uribe‐Uribe
Norma Uribe‐Uribe
DADiana Aguilar‐León
Diana Aguilar‐León
CNCarlos A. Nuñez‐Álvarez
Carlos A. Nuñez‐Álvarez
GTGonzalo Torres-Villalobos
Gonzalo Torres-Villalobos